Gradient™ Denervation System
Pulmonary Hypertension due to Left Heart Disease (Group 2 PH, including CpcPH)
Key Facts
About Gradient Denervation Technologies
Gradient Denervation Technologies is a private, clinical-stage medical device company addressing a large unmet need in cardiovascular medicine. Its core technology is a purpose-built pulmonary artery denervation (PADN) system that uses therapeutic ultrasound to ablate nerves around the pulmonary artery, aiming to reduce pulmonary pressure. The company has gained significant regulatory momentum, including FDA Breakthrough Device designation and acceptance into the FDA's Total Product Life Cycle Advisory Program, and is advancing an early feasibility study in the U.S. With intellectual property originating from Stanford University and a seasoned leadership team, Gradient is positioned as a pioneer in a therapeutic area with no currently approved device or drug therapies.
View full company profile